Do analysts prefer XCUR or APLM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, XCUR or APLM?

Exicure has higher earnings, but lower revenue than Apollomics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exicure $500K 17.84 -$4.95M -$1.55 N/A Apollomics $8.50M 4.52 -$10.94M N/A N/A

Is XCUR or APLM more profitable?

Apollomics' return on equity of 0.00% beat Exicure's return on equity. Company Net Margins Return on Equity Return on Assets Exicure N/A -179.41% -64.37% Apollomics N/A N/A N/A

Is ENLV or XCUR more profitable?

Enlivex Therapeutics' return on equity of 248.08% beat Exicure's return on equity. Company Net Margins Return on Equity Return on Assets Enlivex Therapeutics N/A 248.08% 206.39% Exicure N/A -179.41% -64.37%

Do analysts prefer XCUR or LTRN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lantern Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is XCUR or LTRN more profitable?

Exicure's return on equity of -179.41% beat Lantern Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Exicure N/A -179.41% -64.37% Lantern Pharma N/A -198.34% -129.08%

Do analysts rate XCUR or DYAI?

Dyadic International has a consensus target price of $3.00, indicating a potential upside of 201.51%. Given Dyadic International's stronger consensus rating and higher probable upside, analysts clearly believe Dyadic International is more favorable than Exicure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Dyadic International 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Do analysts recommend XCUR or FTH?

Sensei Biotherapeutics has a consensus target price of $54.90, indicating a potential upside of 99.64%. Given Sensei Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Sensei Biotherapeutics is more favorable than Exicure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Sensei Biotherapeutics 1 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.83

Is XCUR or FTH more profitable?

Exicure's return on equity of -179.41% beat Sensei Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Exicure N/A -179.41% -64.37% Sensei Biotherapeutics N/A -1,012.17% -175.69%

Exicure (XCUR) Competitors

$1.36 +0.01 (+0.74%)

As of 12:34 PM Eastern

Compare

XCUR vs. APLM, ENLV, LTRN, DYAI, and FTH

Should you buy Exicure stock or one of its competitors? MarketBeat compares Exicure with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Exicure include Apollomics (APLM), Enlivex Therapeutics (ENLV), Lantern Pharma (LTRN), Dyadic International (DYAI), and Sensei Biotherapeutics (FTH). These companies are all part of the "biotechnology" industry.

How does Exicure compare to Apollomics?

Exicure (NASDAQ:XCUR) and Apollomics (NASDAQ:APLM) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, earnings and risk.

In the previous week, Apollomics had 1 more articles in the media than Exicure. MarketBeat recorded 1 mentions for Apollomics and 0 mentions for Exicure. Exicure's average media sentiment score of 1.00 beat Apollomics' score of 0.67 indicating that Exicure is being referred to more favorably in the media.

Company	Overall Sentiment
Exicure	Positive
Apollomics	Positive

Exicure has higher earnings, but lower revenue than Apollomics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exicure	$500K	17.84	-$4.95M	-$1.55	N/A
Apollomics	$8.50M	4.52	-$10.94M	N/A	N/A

Exicure has a beta of 3.65, suggesting that its share price is 265% more volatile than the broader market. Comparatively, Apollomics has a beta of 1.46, suggesting that its share price is 46% more volatile than the broader market.

42.8% of Exicure shares are owned by institutional investors. Comparatively, 19.1% of Apollomics shares are owned by institutional investors. 52.8% of Exicure shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Apollomics' return on equity of 0.00% beat Exicure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exicure	N/A	-179.41%	-64.37%
Apollomics	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Exicure beats Apollomics on 6 of the 10 factors compared between the two stocks.

How does Exicure compare to Enlivex Therapeutics?

Enlivex Therapeutics (NASDAQ:ENLV) and Exicure (NASDAQ:XCUR) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk and institutional ownership.

Enlivex Therapeutics presently has a consensus target price of $247.50, suggesting a potential upside of 11,713.84%. Given Enlivex Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Enlivex Therapeutics is more favorable than Exicure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enlivex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

1.0% of Enlivex Therapeutics shares are held by institutional investors. Comparatively, 42.8% of Exicure shares are held by institutional investors. 12.3% of Enlivex Therapeutics shares are held by insiders. Comparatively, 52.8% of Exicure shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Enlivex Therapeutics has higher earnings, but lower revenue than Exicure. Exicure is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enlivex Therapeutics	N/A	N/A	$1.24B	-$8.25	N/A
Exicure	$500K	17.84	-$4.95M	-$1.55	N/A

Enlivex Therapeutics' return on equity of 248.08% beat Exicure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enlivex Therapeutics	N/A	248.08%	206.39%
Exicure	N/A	-179.41%	-64.37%

In the previous week, Enlivex Therapeutics had 10 more articles in the media than Exicure. MarketBeat recorded 10 mentions for Enlivex Therapeutics and 0 mentions for Exicure. Exicure's average media sentiment score of 1.00 beat Enlivex Therapeutics' score of 0.62 indicating that Exicure is being referred to more favorably in the news media.

Company	Overall Sentiment
Enlivex Therapeutics	Positive
Exicure	Positive

Enlivex Therapeutics has a beta of 1.6, meaning that its stock price is 60% more volatile than the broader market. Comparatively, Exicure has a beta of 3.65, meaning that its stock price is 265% more volatile than the broader market.

Summary

Enlivex Therapeutics beats Exicure on 9 of the 15 factors compared between the two stocks.

How does Exicure compare to Lantern Pharma?

Exicure (NASDAQ:XCUR) and Lantern Pharma (NASDAQ:LTRN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, media sentiment, dividends, profitability and analyst recommendations.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Exicure's return on equity of -179.41% beat Lantern Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exicure	N/A	-179.41%	-64.37%
Lantern Pharma	N/A	-198.34%	-129.08%

42.8% of Exicure shares are held by institutional investors. Comparatively, 28.6% of Lantern Pharma shares are held by institutional investors. 52.8% of Exicure shares are held by company insiders. Comparatively, 8.5% of Lantern Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Exicure has higher revenue and earnings than Lantern Pharma. Lantern Pharma is trading at a lower price-to-earnings ratio than Exicure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exicure	$500K	17.84	-$4.95M	-$1.55	N/A
Lantern Pharma	N/A	N/A	-$17.12M	-$1.45	N/A

Exicure has a beta of 3.65, meaning that its stock price is 265% more volatile than the broader market. Comparatively, Lantern Pharma has a beta of 2.35, meaning that its stock price is 135% more volatile than the broader market.

In the previous week, Lantern Pharma had 2 more articles in the media than Exicure. MarketBeat recorded 2 mentions for Lantern Pharma and 0 mentions for Exicure. Exicure's average media sentiment score of 1.00 beat Lantern Pharma's score of 0.21 indicating that Exicure is being referred to more favorably in the media.

Company	Overall Sentiment
Exicure	Positive
Lantern Pharma	Neutral

Summary

Exicure beats Lantern Pharma on 9 of the 11 factors compared between the two stocks.

How does Exicure compare to Dyadic International?

Exicure (NASDAQ:XCUR) and Dyadic International (NASDAQ:DYAI) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, media sentiment, risk, dividends, earnings and institutional ownership.

In the previous week, Dyadic International had 3 more articles in the media than Exicure. MarketBeat recorded 3 mentions for Dyadic International and 0 mentions for Exicure. Exicure's average media sentiment score of 1.00 beat Dyadic International's score of 0.00 indicating that Exicure is being referred to more favorably in the media.

Company	Overall Sentiment
Exicure	Positive
Dyadic International	Neutral

42.8% of Exicure shares are held by institutional investors. Comparatively, 28.0% of Dyadic International shares are held by institutional investors. 52.8% of Exicure shares are held by insiders. Comparatively, 20.9% of Dyadic International shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Exicure has a beta of 3.65, indicating that its share price is 265% more volatile than the broader market. Comparatively, Dyadic International has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market.

Dyadic International has a consensus target price of $3.00, indicating a potential upside of 201.51%. Given Dyadic International's stronger consensus rating and higher probable upside, analysts clearly believe Dyadic International is more favorable than Exicure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Exicure has higher earnings, but lower revenue than Dyadic International. Dyadic International is trading at a lower price-to-earnings ratio than Exicure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exicure	$500K	17.84	-$4.95M	-$1.55	N/A
Dyadic International	$1.67M	21.67	-$7.36M	-$0.23	N/A

Exicure has a net margin of 0.00% compared to Dyadic International's net margin of -192.40%. Exicure's return on equity of -179.41% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exicure	N/A	-179.41%	-64.37%
Dyadic International	-192.40%	-1,005.45%	-77.64%

Summary

Exicure beats Dyadic International on 9 of the 16 factors compared between the two stocks.

How does Exicure compare to Sensei Biotherapeutics?

Exicure (NASDAQ:XCUR) and Sensei Biotherapeutics (NASDAQ:FTH) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk.

Exicure has higher revenue and earnings than Sensei Biotherapeutics. Exicure is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exicure	$500K	17.84	-$4.95M	-$1.55	N/A
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$141.65	N/A

Exicure's return on equity of -179.41% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exicure	N/A	-179.41%	-64.37%
Sensei Biotherapeutics	N/A	-1,012.17%	-175.69%

42.8% of Exicure shares are owned by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are owned by institutional investors. 52.8% of Exicure shares are owned by company insiders. Comparatively, 7.0% of Sensei Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Exicure has a beta of 3.65, meaning that its stock price is 265% more volatile than the broader market. Comparatively, Sensei Biotherapeutics has a beta of -0.25, meaning that its stock price is 125% less volatile than the broader market.

Sensei Biotherapeutics has a consensus target price of $54.90, indicating a potential upside of 99.64%. Given Sensei Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Sensei Biotherapeutics is more favorable than Exicure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sensei Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, Sensei Biotherapeutics had 18 more articles in the media than Exicure. MarketBeat recorded 18 mentions for Sensei Biotherapeutics and 0 mentions for Exicure. Exicure's average media sentiment score of 1.00 beat Sensei Biotherapeutics' score of 0.83 indicating that Exicure is being referred to more favorably in the media.

Company	Overall Sentiment
Exicure	Positive
Sensei Biotherapeutics	Positive

Summary

Exicure beats Sensei Biotherapeutics on 9 of the 15 factors compared between the two stocks.

Get Exicure News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XCUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XCUR vs. The Competition

Export

Metric	Exicure	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$8.92M	$3.71B	$7.03B	$12.96B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-0.90	9.06	269.91	24.87
Price / Sales	17.84	1,278.42	654.69	108.21
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	2.26	17.97	11.40	6.45
Net Income	-$4.95M	-$13.25M	$3.45B	$347.50M
7 Day Performance	-11.39%	5.58%	3.66%	3.77%
1 Month Performance	-20.00%	-1.60%	-0.49%	-0.40%
1 Year Performance	-81.21%	61.32%	77.51%	23.55%

Exicure Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XCUR Exicure	0.6829 of 5 stars	$1.36 +0.7%	N/A	-81.9%	$8.63M	$500K	N/A	50
APLM Apollomics	0.8928 of 5 stars	$17.28 -1.7%	N/A	+209.9%	$38.02M	$8.50M	N/A	45	Gap Up High Trading Volume
ENLV Enlivex Therapeutics	4.0452 of 5 stars	$2.18 +3.3%	$247.50 +11,253.2%	-90.3%	$36.69M	N/A	N/A	70	Gap Down High Trading Volume
LTRN Lantern Pharma	0.6094 of 5 stars	$2.80 +1.8%	N/A	-42.7%	$35.73M	N/A	N/A	20	Upcoming Earnings
DYAI Dyadic International	2.6254 of 5 stars	$0.97 -10.2%	$3.00 +209.4%	+6.7%	$35.33M	$3.09M	N/A	7	News Coverage Upcoming Earnings High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XCUR) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Exicure (XCUR) Competitors

XCUR vs. APLM, ENLV, LTRN, DYAI, and FTH

How does Exicure compare to Apollomics?

Summary

How does Exicure compare to Enlivex Therapeutics?

Summary

How does Exicure compare to Lantern Pharma?

Summary

How does Exicure compare to Dyadic International?

Summary

How does Exicure compare to Sensei Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XCUR vs. The Competition

Exicure Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Exicure (XCUR) Competitors

XCUR vs. APLM, ENLV, LTRN, DYAI, and FTH

How does Exicure compare to Apollomics?

Does the media refer more to XCUR or APLM?

Which has better earnings & valuation, XCUR or APLM?

Which has more risk & volatility, XCUR or APLM?

Do institutionals and insiders have more ownership in XCUR or APLM?

Is XCUR or APLM more profitable?

Do analysts prefer XCUR or APLM?

Summary

How does Exicure compare to Enlivex Therapeutics?

Do analysts prefer ENLV or XCUR?

Do institutionals and insiders have more ownership in ENLV or XCUR?

Which has stronger earnings and valuation, ENLV or XCUR?

Is ENLV or XCUR more profitable?

Does the media refer more to ENLV or XCUR?

Which has more risk and volatility, ENLV or XCUR?

Summary

How does Exicure compare to Lantern Pharma?

Do analysts prefer XCUR or LTRN?

Is XCUR or LTRN more profitable?

Do insiders and institutionals have more ownership in XCUR or LTRN?

Which has preferable valuation & earnings, XCUR or LTRN?

Which has more risk & volatility, XCUR or LTRN?

Does the media prefer XCUR or LTRN?

Summary

How does Exicure compare to Dyadic International?

Does the media prefer XCUR or DYAI?

Do institutionals & insiders hold more shares of XCUR or DYAI?

Which has more volatility & risk, XCUR or DYAI?

Do analysts rate XCUR or DYAI?

Which has stronger earnings & valuation, XCUR or DYAI?

Is XCUR or DYAI more profitable?

Summary

How does Exicure compare to Sensei Biotherapeutics?

Which has stronger valuation & earnings, XCUR or FTH?

Is XCUR or FTH more profitable?

Do insiders & institutionals believe in XCUR or FTH?

Which has more volatility & risk, XCUR or FTH?

Do analysts recommend XCUR or FTH?

Does the media favor XCUR or FTH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XCUR vs. The Competition

Exicure Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools